Nearly half of patients who got a high dose of Eli Lilly’s experimental obesity shot retatrutide lost the equivalent weight of bariatric surgery, sending the drugmaker’s shares up in premarket trading.
Source link
Nearly half of patients who got a high dose of Eli Lilly’s experimental obesity shot retatrutide lost the equivalent weight of bariatric surgery, sending the drugmaker’s shares up in premarket trading.
Source link